

EXHIBIT 25



UNITED STATES DEPARTMENT OF COMMERCE
 Patent and Trademark Office
 Address: COMMISSIONER OF PATENTS AND TRADEMARKS
 Washington, D. C. 20231

| SERIAL NUMBER | FILING DATE | FIRST NAMED APPLICANT | ATTORNEY DOCKET NO. |
|---------------|-------------|-----------------------|---------------------|
| 08/282,874 | 02/28/94 | Lin | 1100931956 |

| EXAMINER | |
|------------|--------------|
| Martirelli | |
| ART UNIT | PAPER NUMBER |
| 1805 | 39 |

DATE MAILED:

EXAMINER INTERVIEW SUMMARY RECORD

All participants (applicant, applicant's representative, PTO personnel):

- (1) Mr. Watt (3) Mr. Odey
 (2) Mr. Beron (4) Exr. Martinelli

Date of interview 05/07/94

Type: Telephonic Personal (copy is given to applicant applicant's representative).

Exhibit shown or demonstration conducted. Yes No. If yes, brief description: None.

Agreement: was reached with respect to some or all of the claims in question. was not reached.

Claims discussed: All.

Identification of prior art discussed: Sugimoto et al

Description of the general nature of what was agreed to if an agreement was reached, or any other comments:
Applicant argued that Sugimoto et al method of making EPO producing hybrid cells is unrepeatable and hence is not enabled. Applicant intends to submit arguments and/or evidence into the record regarding same. The duplicate claim issue was discussed. Applicant intends to amend "enhancing" as suggested. Applicant intends to submit declaration evidence to show that r-EPO differs in glycosylation from any of the naturally occurring EPOs known as of the effective filing date of the instant application and even from the naturally occurring EPOs known since.

(A fuller description, if necessary, and a copy of the amendments, if available, which the examiner agreed would render the claims allowable must be attached. Also, where no copy of the amendments which would render the claims allowable is available, a summary thereof must be attached.)

Unless the paragraphs below have been checked to indicate to the contrary, A FORMAL WRITTEN RESPONSE TO THE LAST OFFICE ACTION IS NOT WAIVED AND MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW (e.g., items 1-7 on the reverse side of this form). If a response to the last Office action has already been filed, then applicant is given one month from this interview date to provide a statement of the substance of the interview.

- It is not necessary for applicant to provide a separate record of the substance of the interview.
 Since the examiner's interview summary above (including any attachments) reflects a complete response to each of the objections, rejections and requirements that may be present in the last Office action, and since the claims are now allowable, this completed form is considered to fulfill the response requirements of the last Office action.

PTOL-413 (REV. 1-84)


 Examiner's Signature

485

546650 FVIII 57006
 607885 ASSAY 4766062
 652218 920
 674308 920
 688622 Abandoned, EPD (4/16/86)
 693258 430 - interference
 729504 assays ~~Abn~~ 920 - Abn 3/13/87
 777657 assays ~~Abn~~ 920 4725537
 781130 pulmon surfact prot Abn
 809971 assay 920 Abn
 811034 assay 4818680 (4/16/87)
 824688 Epo process ISC suspended, Sherry Nolan
 877323 wooling machine
 938201 assay, ISC, pencling no claims + EPD
 058284 cooker ..
 100392 pul surfact 4882422
 136478 isolating mammalian gene, 48B Director
 271293 shock absorber
 862640 FVIII production 18X (chambers) reaction
 386280 sharon nolan ISC, no action
 77796 pat 4725536 (2/16/88) assay
 → Tamenholtz